Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease

Atherosclerosis

Volumn 167, Issue 2, 2003, Pages 293-302

  Lee, Sung Joon ^a,d   Moye, Lemuel A ^b   Campos, Hannia ^a   Williams, Gordon H ^c   Sacks, Frank M ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein B, E, and CIII; Coronary heart disease; Diabetes; Lipoproteins

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEALTH STATUS; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOAFFINITY CHROMATOGRAPHY; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICULATE MATTER; PATIENT; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

EID: 0038265859     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00007-8     Document Type: Article

References (46)

1. Fontbonne A., Eschwege E., Cambien F., Richard J.L., Ducimetiere P., Thibult N., Warnet J.M., Claude J.R., Rosselin G.E. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 32:1989;300-304.
2. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J. 316:1998;823-828.
3. Syvanne M., Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 350:(Suppl. 1):1997;SI20-SI23.
4. Taskinen M.R., Packard C.J., Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 39:1990;1017-1027.
5. Steiner G., Lewis G.F. Hyperinsulinemia and triglyceride-rich lipoproteins. Diabetes. 45:(Suppl. 3):1996;S24-S26.
6. Malmstrom R., Packard C.J., Caslake M., Bedford D., Stewart P., Yki-Jarvinen H., Shepherd J., Taskinen M.R. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 40:1997;454-462.
7. Verges B.L. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab. 25:(Suppl. 3):1999;32-40.
8. Howard B.V., Reitman J.S., Vasquez B., Zech L. Very-low-density lipoprotein triglyceride metabolism in non-insulin-dependent diabetes mellitus. Relationship to plasma insulin and free fatty acids. Diabetes. 32:1983;271-276.
9. Venkatesan S., Imrie H., Read S., Halliday D. Apo C subclasses from non-insulin-dependent diabetic patients - a quantitative comparison with control subjects. Biochem. Soc. Trans. 23:1995;278S.
10. Bren N.D., Rastogi A., Kottke B.A. Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays. Mayo Clin. Proc. 68:1993;657-664.
11. Briones E.R., Mao S.J., Palumbo P.J., O'Fallon W.M., Chenoweth W., Kottke B.A. Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin dependent diabeties. Metabolism. 33:1984;42-49.
12. McConathy W.J., Gesquiere J.C., Bass H., Tartar A., Fruchart J.C., Wang C.S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. 33:1992;995-1003.
13. Ginsberg H.N., Le N.A., Goldberg I.J., Gibson J.C., Rubinstein A., Wang-Iverson P., Norum R., Brown W.V. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78:1986;1287-1295.
14. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75:1985;384-390.
15. Aalto-Setala K., Weinstock P.H., Bisgaier C.L., Wu L., Smith J.D., Breslow J.L. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J. Lipid Res. 37:1996;1802-1811.
16. Agnani G., Bard J.M., Candelier L., Delattre S., Fruchart J.C., Clavey V. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arterioscler. Thromb. 11:1991;1021-1029.
17. Ebara T., Ramakrishnan R., Steiner G., Shachter N.S. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99:1997;2672-2681.
18. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266:1991;18259-18267.
19. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Sussex B., Stampfer M.J., Pleffer M.A., Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:2000;1886-1892.
20. Luc G., Fievet C., Arveiler D., Evans A.E., Bard J.M., Cambien F., Fruchart J.C., Ducimetiere P. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde. J. Lipid Res. 37:1996;508-517.
21. Hodis H.N., Mack W.J., Azen S.P., Alaupovic P., Pogoda J.M., LaBree L., Hemphill L.C., Kramsch D.M., Blankenhorn D.H. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovasiatin. Circulation. 90:1994;42-49.
22. Gervaise N., Garrigue M.A., Lasfargues G., Lecomte P. Triglycerides, apo C3 and LpB:C3 and cardiovascular risk in type II diabetes. Diabetologia. 43:2000;703-708.
23. Chen M., Breslow J.L., Li W., Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. 35:1994;1918-1924.
24. Reddy S., Yang W., Taylor D.C., Shen X., Oxender D., Kust G., Leff T. Mitogen-activated protein kinase regulates transcription of the ApoCIII gene. Involvement of the orphan nuclear receptor HNF4. J. Biol. Chem. 274:1999;33050-33056.
25. Pan X.R., Cheung M.C., Walden C.E., Hu S.X., Bierman E.L., Albers J.J. Abnormal composition of apoproteins C-I, C-II, and C-III in plasma and very-low-density lipoproteins of non-insulin-dependent diabetic Chinese. Clin. Chem. 32:1986;1914-1920.
26. Weisgraber K.H., Innerarity T.L., Harder K.J., Mahley R.W., Milne R.W., Marcel Y.L., Sparrow J.T. The receptor binding domain of human apolipoprotein E. Monoclonal inhibition of binding. J. Biol. Chem. 258:1983;12348-15354.
27. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 341:1989;162-164.
28. Syvanne M., Rosseneu M., Labeur C., Hilden H., Taskinen M.R. Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease; a preliminary report. Atherosclerosis. 105:1994;25-34.
29. Chivot L., Mainard F., Bigot E., Bard J.M., Auget J.L., Madec Y., Fruchart J.C. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis. 82:1990;205-211.
30. Genest J.J. Jr, Bard J.M., Fruchart J.C., Ordovas J.M., Wilson P.F., Schaefer E.J. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis. 90:1991;149-157.
31. Khoo C., Campos H., Judge H., Sacks F.M. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. J. Lipid Res. 40:1999;202-212.
32. Campos H., Perlov D., Khoo C., Sacks F.M. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J. Lipid Res. 42:2001;1239-1249.
33. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl. J. Med. 335:1996;1001-1009.
34. Sacks F.M., Rouleau J.L., Moye L.A., Pfeffer M.A., Warnica J.W., Arnold J.M., Nash D.T., Brown L.E., Sestier F., Rutherford J., et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am. J. Cardiol. 75:1995;621-623.
35. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., Davis B.R., Cole T.G., Pfeffer M.A., Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 98:1998;2513-2519.
36. Pietzsch J., Subat S., Nitzsche S., Leonhardt W., Schentke K.U., Hanefeld M. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim. Biophys. Acta. 1254:1995;77-88.
37. Brousseau T., Clavey V., Bard J.M., Fruchart J.C. Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles. Clin. Chem. 39:1993;960-964.
38. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 3:1996;213-219.
39. Al-Muhtaseb N., Al-Yusef A.R., Bajaj J.S. Lipoprotein lipids and apolipoproteins (AI, AII, B, CII, CIII) in type 1 and type 2 diabetes mellitus in young Kuwaiti women. Diabet. Med. 8:1991;732-737.
40. Castro Cabezas M., de Bruin T.W., de Valk H.W., Shoulders C.C., Jansen H., Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92:1993;160-168.
41. Ikeda T., Ohtani I., Fujiyama K., Hoshino T., Tanaka Y., Tekeuchi T., Mashiba H. Apolipoprotein levels in non-insulin-dependent diabetes mellitus with clinical macroangiapathy. Diabete Metab. 17:1991;373-378.
42. Dallongeville J.M.A., Cottel D., Fruchart J.C., Amouyel P., Helbecque N. Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans. Int. J. Obes. Relat. Metab. Disord. 25:2001;1012-1017.
43. Elam M.B., Wilcox H.G., Cagen L.M., Deng X., Raghow R., Kumar P., Heimberg M., Russell J.C. Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. J. Lipid Res. 42:2001;2039-2048.
44. Vance J.E., Russell J.C. Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J. Lipid Res. 31:1990;1491-1501.
45. Batal R., Tremblay M., Barrett P.H., Jacques H., Fredenrich A., Mamer O., Davignon J., Cohn J.S. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41:2000;706-718.
46. Ishibashi S., Yamada N., Shimano H., Takaku F., Akanuma Y., Murase T. Composition of very-low-density lipoproteins in non-insulin-dependent diabetes mellitus. Clin. Chem. 35:1989;808-812.